Pfizer Stock Price Surges After Better Than Expected Q3 Earnings
Pfizer Inc. (NYSE: PFE) reported a robust third-quarter performance, driven by stronger-than-anticipated sales of its COVID-19 antiviral treatment Paxlovid. The drugmaker’s total revenue reached $17.7 billion, a 31% increase compared to last year’s third quarter, surpassing analysts’ projections of $14.92 billion. Adjusted earnings per share came in at $1.06, well above the expected $0.61. Why … Read more